Skip to content

Study of Effect of Purgation therapy( virechan) on Serum IgE antibody Level In Atopic Dermatitis(Eczema)

Study Of Effect of Virechan On Serum IgE Level in Atopic Dermatitis - NIL

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/06/069620
Enrollment
30
Registered
2024-06-27
Start date
Unknown
Completion date
Unknown
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L209- Atopic dermatitis, unspecified

Interventions

None listed

Sponsors

Ayurvedic and Unani Tibbia college and hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patient with known case of atopic dermatitis along with specific symptomatology of atopic dermatitis according to criteria of American academy dermatology of eczema with increased IgE level . 2.Patient of Age group 18-60 years of either sex.

Exclusion criteria

Exclusion criteria: 1.Patients who are contraindicated for virechana karma- like lower GI bleeding, Prolapse of rectum, incontinence of stool etc. will not be included in the trial group 2. Patients of other skin disorders (like psoriasis,seborrheic dermatitis ,scabies,contact dermatitis,lupus erythematous etc.) . 3. Patients with comorbid condition such as Diabetes mellitus(having HbA1c greater than 7.5 percent with or without antihyperglycemic medication). 4. Patients with renal or hepatic impairment (Sr. creatinine greater than 1.8 mg/dl, SGOT and SGPT greater than Five times of upper limit . 5. Patients who are taking immunomodulatory drug since last 2 month, antitubercular ,anti-retroviral drugs,steroids,antibiotics, etc . 6. Patients requiring emergency treatment

Design outcomes

Primary

MeasureTime frame
Proportion of patients showing mean reduction in Sr. IgE levelTimepoint: Proportion of Patients showing mean reduction in Sr. IgE level,7days After completion of trial

Secondary

MeasureTime frame
Proportion of patients showing mean reduction in Srhistamine level and cytokine profile (IL4,IL13) from baseline to 29 days • Proportion of patients showing mean reduction in subjective criteria like SCORAD score,DLQI, EASI,ItchNRS Scale from baseline to 29 days.Timepoint: 0 to 29 days

Countries

India

Contacts

Public ContactDr satrughna Behera

Ayuvedic and unani Tibbia College and Hospital, Karol Bagh, New Delhi

manojshamkuwar@gmail.com9354925019

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026